The Accelerated Medical Partnership (AMP) program is a public-private partnership between the National Institutes of Health, the U.S. Food and Drug Administration, biopharmaceutical companies, and other organizations that aim to transform the current model for developing new diagnostics as well as treatments. The collaborative efforts by pharaceutical companies include sharing expertise and resources in an integrated governance structure that enables the best-informed contributions from all participants. Development of a new drug has historically taken over a decade with a high failure rate. The AMP program envelopes a unified goal to compress the timelines, reduce costs, and increase success rates of targeted therapies. "Through this effort, AMP partners have developed research plans and are sharing costs, expertise, and resources in an integrated governance structure that enables the best informed contributions to science from all participants" (Washington: NIH, industry and non-profits join forces to speed validation of disease targets, 2014). "Provider consolidation takes many forms, but the general trend can make it easier to share electronic records systems, coordinate care of patients, and eliminate redundant costs. Another potential benefit of integrated health systems is in addressing the persistent problem of variation in health care practice and outcomes, particularly in surgery" (Birkmeyer, 2015)